Antineoplastic agents: Classification and mechanisms of action

Chemotherapy for Gynecological Neoplasms: Current Therapy and Novel Approaches

Volumn , Issue , 2004, Pages 1-11

  Aoki, Rui ^a   Kavanagh, John J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34447297695     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (74)

1. Cohen JL, Jao JY. Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat. J Pharmacol Exp Ther 1970; 174(2):206–210.
2. Colvin M, Hilton J. Pharmacology of cyclophosphamide and metabolites. Cancer Treat Rep 1981; 65(suppl 3):89–95.
3. Allen LM, Creaven PJ. Activation of the antineoplastic drug isophosphamide with bovine serum albumin and rat liver microsomes. J Pharm Pharmacol 1972; 24(7):585–586.
4. Allen LM, Creaven PJ. In vitro activation of isophosphamide (NSC 109724), a new oxazaphosphorine, by rat-liver microsomes. Cancer Chemother Rep 1972; 56(5):603– 610.
5. Low JE, Borch RF, Sladek NE. Further studies on the conversion of 4-hydroxyoxaphos-phorines to reactive mustards and acrolein in inorganic buffers. Cancer Res 1983; 43(12): 5815–5820.
6. Dorr RT. Chemoprotectants for cancer chemotherapy. Semin Oncol 1991; 18(suppl 2):48– 58.
7. Boal JH, Williamson M, Boyd VL, Ludeman SM, Egan W. 31P NMR studies of the kinetics of bisalkylation by isophosphoramide mustard: comparisons with phosphoramide mustard. J Med Chem 1989; 32(8):1768–1773.
8. Brookes P. On the interaction of carcinogens with DNA. Biochem Pharm 1971; 20(5):999– 1003.
9. Chang SY, Evans TL, Alberts DS. The stability of melphalan in the presence of chloride ion. J Pharm Pharmacol 1979; 31(12):853–854.
10. Goldenberg GJ, Lam HY, Begleiter A. Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1plasmacytoma cells in vitro. J Biol Chem 1979; 254(4):1057–1064.
11. Begleiter A, Grover J, Goldenberg GJ. Uptake and metabolism of hexamethylmelamine and pentamethylmelamine L5178Y lymphoblasts in vitro. Cancer Res 1980; 40(12):4489– 4494.
12. Garattini E, Colombo T, Donelli MG, Catalani P, Bianchi M, D’Incalci M, Pantarotto C. Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma. Cancer Chemother Pharmacol 1983; 11(1):51–55.
13. Rutty CJ, Connors TA, Nguyen Hoang N, Do Cao T, Hoellinger H. In vivo studies with hexamethylmelamine. Eur J Cancer 1978; 14(6):713–720.
14. Wells RD, Larson JE. Studies on the binding of actinomycin D to DNA and DNA model polymers. J Mol Biol 1970; 49(2):319–342.
15. Waterloh K, Fox KR. Secondary (non-GpC) binding sites for actinomycin on DNA. Biochem Biophys Acta 1992; 1131(3):300–306.
16. Reich E. Possible approaches to further actinomycin studies. Cancer Chemother Rep 1974; 58(1):79–80.
17. Inaba M, Johnson RK. Decreased retention of actinomycin D as the basis for cross resistance in anthracycline resistant sublines of P388 leukemia. Cancer Res 1977; 37 (12):4629–4634.
18. Cotter TG, Glynn JM, Escheverri F, Green DR. The induction of apoptosis in cells of the immune system by cytotoxic stimuli. Sem Immunol 1992; 4(6):399–405.
19. Reddy MV, Randerath K. 32P-Analysis of DNA adducts in somatic and reproductive tissues of rats treated with the anticancer antibiotic mitomycin C. Mutat Res 1987; 179(1):75–88.
20. Tomasz M, Lipman R, Lee MS, Verdine GL, Nakanishi K. Reaction of acid-activated mitomycin C with calf thymus DNA and model guanines: elucidation of the base-catalyzed degradation of N7-alkylguanine nucleosides. Biochemistry 1987; 26(7):2010–2027.
21. Kennedy KA, Rockwell S, Sartorelli AC. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res 1980; 40(7):2356–2360.
22. 2: a ferrous oxidase. Mol Pharmacol 1979; 16(1):256–260.
23. Barlogie B, Drewinko B, Schumann J, Freireich EJ. Pulse cytophotometric analysis of cell cycle perturbation with bleomycin in vitro. Cancer Res 1976; 36(3):1182–1187.
24. Rice JA, Crothers DM, Pinto AL, Lippard SJ. The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by approximately 40j toward the major groove. Proc Natl Acad Sci USA 1988; 85(12):4158–4161.
25. Plooy AC, van Dijk M, Lohman PH. Induction and repair of DNA cross-links in Chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res 1984; 44(5):2043–2051.
26. Bellon SF, Coleman JH, Lippard SJ. DNA unwinding produced by site-specific intra-strand cross-links of the antitumor drug cis-diamminedichloroplatinum. Biochemistry 1991; 30(32):8026–8035.
27. Kastan MB, Zhang Q, el-Diery WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71(4):587–597.
28. Gralla JD, Sasse-Dwight S, Poljak JG. Formation of blocking lesions at identical DNA sequences by the nitrosourea and platinum classes of anticancer drugs. Cancer Res 1987; 47(19):5092–5096.
29. Corda Y, Anin MF, Leng M, Job D. RNA polymerases react differently at d(ApG) and d(GpG) adducts in DNA modified by cis-diamminedichloroplatinum (II). Biochemistry 1992; 31(7):1904–1908.
30. Balcarova Z, Mrazek J, Keinwachter V, Brabec V. Cleavage by restriction enzymes of DNA modified with the antitumor drug cis-diamminedichloroplatinum (II). Gen Physiol Biophys 1992; 11(6):579–588.
31. Butour JL, Magard AM, Vieussens C, Johnson NP. Kinetic studies of the hydrolysis of platinum–DNA complexes by nuclease S1. Chem Biol Interact 1990; 73(2–3):195–205.
32. Uozumi J, Litterst CL. The effect of cisplatin on renal ATPase activity in vivo and in vitro. Cancer Chemother Pharmacol 1985; 15(2):93–96.
33. Gordon JA, Gattone VH. Mitochondrial alterations in cisplatin-induced acute renal failure. Am J Physiol 1986; 250(6 pt 2):F991–F998.
34. Peyrot V, Briand C, Monburg R, Sari JC. In vitro mechanism study of microtubule assembly inhibition by cis-dichloro-diammine-platinum. Biochem Pharmacol 1986; 35 (3):371–375.
35. Micetich KC, Barnes D, Erickson JC. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum (II) and cis-diamminedichloroplatinum (II) on L1210 cells. Cancer Res 1985; 45(9):4043–4047.
36. Sundquist WI, Lippard SJ, Stollar BD. Monoclonal antibodies to DNA modified with cisor trans-diamminedichloroplatinum (II). Proc Natl Acad Sci USA 1987; 84(23):8225– 8229.
37. Harrap KR. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 1985; 12(suppl A):21–33.
38. Priest DG, Bunni M, Sirotnak FM. Relationship of reduced folate changes to inhibition of DNA synthesis induced by methotrexate in L1210 cells in vivo. Cancer Res 1989; 49 (15):4204–4209.
39. Bunni M, Doig MT, Donato H, Kesavan V, Priest DG. Role of methylenetetrahydrofolate depletion in methotrexate-mediated intracellular thymidylate synthesis inhibition in cultured L1210 cells. Cancer Res 1988; 48(12):3398–3404.
40. Baram J, Chabner BA, Drake JC, Fitzhugh AL, Scholar PW, Allegra CJ. Identification and biochemical properties of 10-formyl dihydrofolate, a novel folate found in meth-otrexate-treated cells. J Biol Chem 1988; 263(15):7105–7111.
41. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase methotrexate polyglutamates. J Biol Chem 1985; 260(17):9720– 9726.
42. Lyons SD, Sant ME, Christopherson RI. Cytotoxic mechanisms of glutamine antagonists in mouse L1210 leukemia. J Biol Chem 1990; 265(19):11377–11381.
43. Houghton JA, Houghton PJ. Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma. Eur J Clin Oncol 1983; 19(6):807– 815.
44. Santi DV, McHenry CS, Sommer A. Mechanisms of interactions of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974; 13(3):471–481.
45. Rustum YM. Biochemical rationale for the 5-fluorouracil leucovorin combination and update of clinical experience. J Chemother 1990; 2(suppl 1):5–11.
46. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2V2V-difluorode-oxycytidine on DNA synthesis. Cancer Res 1991; 51(7):6110–6117.
47. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995; 6(suppl 6):7–13.
48. Howard SM, Theologides A, Sheppard JR. Comparative effects of vindesine, vinblastine, and vincristine on mitosis arrest and hormone response of L1210 leukemia cells. Cancer Res 1980; 40(8 pt 1):2695–2700.
49. Shrek R, Stefani SS. Toxicity of microtubular drugs to leukemic lymphocytes. Exp Mol Pathol 1981; 34(3):369–378.
50. Zakhireh B, Malech HL. The effect of colchicine and vinblastine on the chemotactic response of human monocytes. J Immunol 1980; 125(5):2143–2153.
51. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979; 277(5698):665–667.
52. Wilson L, Miller HP, Farrell KW, Snyder KB, Thompson WC, Purich DL. Taxol sta-bilization of microtubules in vitro: dynamics of tubulin addition and loss at opposite microtubule ends. Biochemistry 1985; 24(19):5254–5262.
53. Jordan MA, Toso RJ, thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90(20): 9552–9556.
54. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993; 19(4):351–386.
55. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry and competition. Biochemistry 1993; 32(11):2747–2755.
56. Keller HU, Zimmermann A. Shape changes and chemokinesis of Walker 256 carcino-sarcoma cells in response to colchicine, vinblastine, nocodazole, and Taxol. Invasion Metastasis 1986; 6(1):33–43.
57. cdc2 coincident with Taxol-induced apoptosis. Cell Growth Diff 1994; 5(10):1041–1050.
58. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58:351–375.
59. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58:351–375.
60. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994; 20(1):73–96.
61. Wang JC. DNA topoisomerases. Ann Rev Biochem 1996; 65:635–692.
62. Tsao YP, Russo A, Nyamuswa G, Silber R, Liu LF. Interaction between replication forks and topoisomerase I–DNA cleavage complexes: studies in a cell-free SV-40 DNA replication system. Cancer Res 1993; 53(24):5908–5914.
63. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994; 34:191–218.
64. Nelson EM, Tewey KM, Liu LF. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4V-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci USA 1984; 81(5):1361–1365.
65. Adachi Y, Luke M, Laemmli UK. Chromosome assembly in vitro: topoisomerase II is required for condensation. Cell 1991; 64(1):137–148.
66. Ross W, Rowe T, Glisson B, Yalowich J, Liu L. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 1984; 44(12 pt 1):5857–5860.
67. Smith PJ, Anderson CO, Watson JV. Predominant role for DNA damage in etoposide-induced cytotoxicity and cell cycle perturbation in human SV40-transformed fibroblasts. Cancer Res 1986; 46(11):5641–5645.
68. Kim SH, Kim JH. Lethal effect of adriamycin on the division cycle of HeLa cells. Cancer Res 1972; 32(2):323–324.
69. Glisson BS, Ross WE. DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther 1987; 32(2):89–106.
70. Capranico G, Kohn KW, Pommier Y. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res 1990; 18(22):6611–6619.
71. Trist H, Phillips DR. In vitro transcription analysis of the role of flanking sequence on the DNA sequence specificity of Adriamycin. Nucleic Acids Res 1989; 17(10):3673–3688.
72. Ubezio P, Civoli F. Flow cytometric detection of hydrogen peroxide production induced by doxorubicin in cancer cells. Free Rad Biol Med 1994; 16(4):509–516.
73. 2. J Free Rad Biol Med 1985; 1(1):43–49.
74. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994; 54(8):2095–2097.